Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Safety, Tolerability, Efficacy, Pharmacokinetics, and Pharmacodynamics of Single Rising i.v. (Stage 1) and s.c. (Stage 2) Doses of BI 655066 in Male and Female Patients With Moderate to Severe Psoriasis (Randomised, Double-blind, Placebo-controlled Within Dose Groups)

NCT01577550 is registered in ClinicalTrials.gov with AbbVie as lead sponsor.

NCT NCT01577550
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01577550 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Safety, Tolerability, Efficacy, Pharmacokinetics, and Pharmacodynamics of Single Rising i.v. (Stage 1) and s.c. (Stage 2) Doses of BI 655066 in Male and Female Patients With Moderate to Severe Psoriasis (Randomised, Double-blind, Placebo-controlled Within Dose Groups)
Lead sponsor
AbbVie
Phase
Phase 1
Overall status
Completed
Start date
April 30, 2012
Completion date
May 31, 2014
Enrollment
39 (actual)
Sites
9

Conditions

As the registry lists them; a condition with its own page is linked.

psoriasis